Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksExperian Regulatory News (EXPN)

Share Price Information for Experian (EXPN)

Share Price is delayed by 15 minutes
Get Live Data
2,520.00    15.00 (0.60%)
Bid:
2,521.00
Ask:
2,523.00
Spread: 2.00 (0.079%)
Market Cap: £22.40b
EXPN Live PriceLast checked at - London Stock Exchange

Intraday Experian Share Chart

Chair appointment

21 Apr 2026 07:00

RNS Number : 2049B
Experian plc
21 April 2026
 

 

news release

 

 

EXPERIAN PLC CHAIR APPOINTMENT

21 April 2026 - Experian plc, the global data and technology company, today announces that Adam Crozier will join the Board as an independent Non-Executive Director and Chair Designate from 12 May 2026, and will succeed Mike Rogers as Chair following the conclusion of the Experian plc Annual General Meeting to be held on 22 July 2026. This follows the Company's previous announcement that Mike will retire as a Director and Chair of Experian plc at the conclusion of the AGM, having served on the Board for nine years, including a highly successful seven year tenure as Chair. Adam Crozier will also serve on the Remuneration and Nomination & Corporate Governance Committees, and Chair the latter following the AGM.

Adam Crozier is an experienced Chair and former FTSE 100 Chief Executive with a strong track record of leading large consumer-facing organisations. He is currently Chair of BT Group plc, where he also chairs the Nomination Committee and has responsibility for security oversight. He is also Chair of Kantar Group, a data, analytics and brand consulting company. His career spans senior leadership roles across multiple sectors, with particular experience in brand-led businesses and in driving digital and operational transformation.

Adam was also previously Chair of Whitbread PLC and ASOS plc, and a Non-Executive Director of Sony Group Corporation.

Alison Brittain, Senior Independent Director, said: "Following a comprehensive and rigorous search process, the Board is delighted to appoint Adam as Chair. He brings extensive experience of leading large, complex organisations and a strong track record in data-driven and technology-enabled businesses. Adam's strategic judgement, extensive Chair experience and measured approach position him well to support the Company's continued growth, and the Board looks forward to the perspective he will bring to Experian during the next phase of its development."

Brian Cassin, Chief Executive Officer, said: "On behalf of the Board and everyone at Experian, I would like to thank Mike Rogers for his significant contribution over many years, both as Chair and previously as a Non-Executive Director. His leadership has been instrumental in the Company's development, and we are grateful for his guidance and support.

"We are very pleased to welcome Adam to the Board. He brings extensive leadership and Board experience across large, international businesses, and his insight will be valuable as we continue to execute our strategy and deliver long-term growth."

Adam Crozier said: "I am delighted to be joining Experian at an important stage in its development. The Company has built a strong track record of growth, underpinned by its data, technology and deep customer relationships, and is well positioned to capitalise on the opportunities ahead. I look forward to working with the Board and management team to support continued successful execution of its strategy and delivery of long-term value for stakeholders."

Mike Rogers, Chair, said: "It has been a privilege to serve on the Board of Experian since 2017 and as Chair over the past seven years, and I am pleased to welcome Adam to the Board, and as my successor as Chair. The Company is well positioned for the future, and I am confident it will continue to deliver sustained success. I would like to thank my fellow Board members for their support and wish Experian every success in the years ahead."

The Company confirms, save as disclosed above, that there are no details to be disclosed under UK Listing Rule 6.4.8R, paragraphs (1) to (6) in respect of Adam Crozier's appointment.

Contact:

Experian

Nadia Ridout-Jamieson Investor queries +44 (0)20 3042 4220

Gerry Tschopp, Nick Jones Media queries

 

Teneo

Graeme Wilson and Louise Male +44 (0)20 7353 4200

 

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPLEAELKEFA
Date   Source Headline
4th Apr 20246:00 pmRNSExperian to acquire Illion in ANZ
3rd Apr 20249:30 amRNSDirector/PDMR Shareholding
28th Mar 202411:05 amRNSTotal Voting Rights
21st Mar 202412:15 pmRNSBlock listing Interim Review
20th Mar 20248:47 amRNSAdditional Listing
14th Mar 20242:08 pmRNSAdditional Listing
6th Mar 20249:15 amRNSAdditional Listing
4th Mar 202411:45 amRNSExperian signs new Revolving Credit Facility
29th Feb 202411:30 amRNSTotal Voting Rights
28th Feb 202410:15 amRNSDirector/PDMR Shareholding
28th Feb 20249:15 amRNSAdditional Listing
21st Feb 20249:15 amRNSAdditional Listing
14th Feb 20249:15 amRNSAdditional Listing
7th Feb 20249:14 amRNSAdditional Listing
6th Feb 20243:47 pmRNSDirector/PDMR Shareholding
31st Jan 202410:00 amRNSTotal Voting Rights
31st Jan 20249:20 amRNSAdditional Listing
24th Jan 20249:47 amRNSAdditional Listing
17th Jan 202412:44 pmRNSDirector/PDMR Shareholding
17th Jan 20249:44 amRNSAdditional Listing
16th Jan 20247:00 amRNSExperian Q3 FY24 trading update
12th Jan 20245:44 pmRNSFirst Interim Dividend
10th Jan 202410:55 amRNSAdditional Listing
3rd Jan 20249:02 amRNSAdditional Listing
29th Dec 202310:03 amRNSTotal Voting Rights
15th Dec 20239:32 amRNSElections for first interim dividend
13th Dec 20239:31 amRNSAdditional Listing
6th Dec 20239:14 amRNSAdditional Listing
30th Nov 202312:14 pmRNSTotal Voting Rights
29th Nov 20239:43 amRNSAdditional Listing
22nd Nov 20239:25 amRNSAdditional Listing
15th Nov 20237:00 amRNSHalf-year Report
10th Nov 20239:00 amRNSDirector Declaration
31st Oct 20235:04 pmRNSTransaction in Own Shares
31st Oct 202312:22 pmRNSTotal Voting Rights
30th Oct 20235:13 pmRNSTransaction in Own Shares
27th Oct 20235:32 pmRNSTransaction in Own Shares
26th Oct 20235:44 pmRNSTransaction in Own Shares
25th Oct 20235:17 pmRNSTransaction in Own Shares
24th Oct 20235:42 pmRNSTransaction in Own Shares
11th Oct 20239:46 amRNSAdditional Listing
6th Oct 20233:30 pmRNSShare repurchase programme
4th Oct 20239:04 amRNSAdditional Listing
27th Sep 20235:07 pmRNSTransaction in Own Shares
27th Sep 20239:50 amRNSAdditional Listing
26th Sep 20235:08 pmRNSTransaction in Own Shares
25th Sep 20235:47 pmRNSTransaction in Own Shares
20th Sep 20239:13 amRNSAdditional Listing
19th Sep 20232:45 pmRNSBlock listing Interim Review
13th Sep 20239:30 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.